

### Nomination for Ordinary Executive Committee Member

Annual General Meeting, Tuesday 13 May 2025

Joint Congress of ESPE and ESE 2025, Copenhagen, Denmark

### Form B

Please return to: Professor M Zatelli, Secretary, European Society of Endocrinology, Redwood House, Brotherswood Court, Great Park Road, Bradley Stoke, Bristol, BS32 4QW, UK or email to [info@ese-hormones.org](mailto:info@ese-hormones.org)

Please refer the [Information on the role of an ESE Executive Committee member](#) for detailed information on the role and time commitment. Important information is also detailed in the [Trustees' responsibilities: Key points for Executive Committee candidates](#).

**Closing date: Monday 6 January 2025**

1	Name of Nominee:	Corin Badiu
2	Nationality:	Romanian
3	Email address:	<a href="mailto:badicrin@yahoo.co.uk">badicrin@yahoo.co.uk</a>
4	Current position and geographical location:	Head of Department Endocrinology 4, National Institute of Endocrinology, "C. Davila" University of Medicine and Pharmacy, Bucharest, Romania
5	Speciality in endocrinology/Main field of expertise:	Neuroendocrinology, Thyroid cancer
6	Basic, clinical or both:	Both
7	Give details of current or previous committee experience in a national society of endocrinology or a European speciality society:	President of the RomanianPsychoNeuroEndocrine Society 2011-2022 Member of the Board- Romanian Endocrine Society 2005-2018 Member of the Congress Committee of ESE 2021-2025
8	Give details of experience as an editor or member of an editorial board:	Editor in Chief- Acta Endocrinologica Bucharest, 2016 – 2025 Member of Editorial Board – Frontiers in Endocrinology, Hormones - International Journal of Endocrinology and Metabolism
9	List (max) 10 papers that were published in international journals within the last 6 years. Note: journals to have an impact factor of 2.0 or above.	<ol style="list-style-type: none"> <li>Lider-Burciulescu SM, Gheorghiu M, Braha E, Stanescu LS, Patocs A, <b>Badiu C</b>. Genetic landscape of Romanian PPGLs. J Cell Mol Med. 2024 Dec;28(23):e70204. <b>IF 4,3</b></li> <li>Moreno-Reyes R, Feldt-Rasmussen U, Piekietko-Witkowska A, Gaspar da Rocha A, <b>Badiu C</b>, Koehrlé J, Duntas L. The ETA-ESE statement on the European Chemicals Agency opinion on iodine as an endocrine disruptor. Eur Thyroid J. 2024 Feb 1;13(1):e230244. <b>IF 3,5</b></li> <li><b>Badiu C</b>, Witek P. Editorial: Insights Into Acromegaly Complications. Front Endocrinol (Lausanne) 2022; 13:905145. <b>IF: 3.9</b></li> <li><b>Badiu C</b>. From oxygen sensors to neuroendocrine tumours. Nat Rev Endocrinol 2022; 18(8):456. <b>IF: 31</b></li> <li>Capdevila J, Klochikhin A, Leboulleux S, Isaev P, <b>Badiu C</b>, Robinson B, Hughes BGM, Keam B, Parnis F, Elisei R, Gajate P, Gan HK, Kapiteijn E, Locati L, Mangeshkar M, Faoro L, Krajewska J, Jarzab B. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid. 2022 May;32(5):515-524. <b>IF: 6</b></li> <li>Pivonello R, Zacharieva S, Elenkova A, Tóth M, Shimon I, Stigliano A, <b>Badiu C</b>, Brue T, Georgescu CE, Tsagarakis S, Cohen F, Fleseriu M. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary. 2022 Dec;25(6):911-926. <b>IF: 3.3</b></li> <li>Negggers S, <b>Badiu C</b>, Biagetti B, Durand-Gasselín L, Petit A, Petrossians P, Regnault B, Rich D, Shafigullina Z, Shustov S, Vydrych A. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly. Expert Rev Clin Pharmacol. 2021 Dec;14(12):1551-1560. <b>IF: 3.6</b></li> <li>Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, Dutcus CE, Suzuki T, Ren M, Wirth LJ. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-</li> </ol>

		<p>refractory differentiated thyroid cancer. Eur J Cancer. 2021 Apr;147:51-57. <b>IF: 7.6</b></p> <p>9. Martel-Duguech LM, Jorgensen JOL, Korbonits M, Johannsson G, Webb SM, Amadidou F, Mintziori G, Arosio M, Giavoli C, <b>Badiu C</b>, Boschetti M, Ferone D, Ricci Bitti S, Brue T, Albarel F, Cannavò S, Cotta OR, Carvalho D, Salazar D, Christ E, Debono M, Dusek T, Garcia-Centeno R, Ghigo E, Gasco V, Góth MI, Oláh D, Kovacs L, Höybye C, Kocjan T, Mlekuš Kozamernik K, Kužma M, Payer J, Medic-Stojanoska M, Novak A, Miličević T, Pekic S, Miljic D, Perez Luis J, Pico AM, Preda V, Raverot G, Borson-Chazot F, Rochira V, Monzani ML, Sandahl K, Tsagarakis S, Mitravela V, Zacharieva S, Zilaitiene B, Verkauskiene R. ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. Eur J Endocrinol. 2020 Dec 1:EJE-20-1180.R1. <b>IF: 5.3</b></p> <p>10. Canu L, Van Hemert JAW, Kerstens MN, Hartman RP, Khanna A, Kraljevic I, Kastelan D, <b>Badiu C</b>, Ambroziak U, Tabarin A, Haissaguerre M, Buitenwerf E, Visser A, Mannelli M, Arlt W, Chortis V, Bourdeau I, Gagnon N, Buchy M, Borson-Chazot F, Deutschbein T, Fassnacht M, Hubalewska-Dydejczyk A, Motyka M, Rzepka E, Casey RT, Challis BG, Quinkler M, Vroonen L, Spyroglou A, Beuschlein F, Lamas C, Young WF, Bancos I, Timmers HJLM. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab. 2019 Feb 1;104(2):312-318. <b>IF: 5</b></p>
10	Give details of any experience with EU funding:	Participant into several COST programs: action CA20122 “Harmonizing clinical care and research on adrenal tumours in European countries, 2021-2025”- Responsible for Romania; BM1105-GnRH deficiency: Elucidation of the neuroendocrine control of human reproduction: 2012-2016, member in Romanian team